Evidence map›Paper›PMID 39204763›Full record

ArticlePlants (Basel, Switzerland)2024

The Application of Paclobutrazol to GA

Samuel D Nomo, Aeden Shlebe, Shimon Rachmilevitch, Akiva Shalit-Kaneh

Abstract read
In one paragraph

Article in Plants (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Samuel D NomoDepartment of Vegetables and Field Crops, Institute of Plant Sciences Agricultural Research Organization, Gilat Research Center, M.P. Negev, Gilat 85280, Israel.
Aeden ShlebeDepartment of Vegetables and Field Crops, Institute of Plant Sciences Agricultural Research Organization, Gilat Research Center, M.P. Negev, Gilat 85280, Israel.
Shimon RachmilevitchFrench Associates Institute for Agriculture and Biotechnology of Drylands, The Jacob Blaustein Institutes for Desert Research, Sede Boqer Campus, Ben-Gurion University of the Negev, Sede Boqer 849900, Israel.ORCID 0000-0003-3600-5949
Akiva Shalit-KanehDepartment of Vegetables and Field Crops, Institute of Plant Sciences Agricultural Research Organization, Gilat Research Center, M.P. Negev, Gilat 85280, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Potato seed tubers are a valuable product in potato agriculture. Over the years, studies have been conducted to increase the fraction of mid-size tubers, which are used as a planting material, within the general pool of tuber sizes. Gibberellic acid has been a central component of such studies and has successfully increased the seed-size pool. However, in many cases, misshapen tubers were formed, and the practice has not become widespread. The use of the gibberellic acid inhibitor paclobutrazol has been examined for its ability to increase seed tuber number and tuber growth and to overcome the heat inhibition of tuberization in warm climates. Paclobutrazol has been shown to increase tuber yield and growth rate. In this study, we aimed to test whether the combination of gibberellic acid and paclobutrazol can increase the seed tuber pool, reduce the number of misshapen tubers, and shorten the growth cycle, thus avoiding end-of-season elevated heat conditions and reducing agricultural inputs. Our findings suggest that gibberellic acid on its own can lead to an increase in the number of seed tubers at earlier stages of growth; however, the sequential addition of paclobutrazol was not able to drive even earlier growth or lower the number of misshapen tubers.

Indexed as

gibberellic acidgrowth cyclepaclobutrazolpotatoseed tubers

Identifiers

PMID39204763
PMCPMC11359537

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.